Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Hematology Diagnostics Market

ID: MRFR/MED/43704-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026

UK Hematology Diagnostics Market Research Report By Product Type (Hematology Analyzers, Fully-automated Hematology Analyzers, Semi-automated Hematology Analyzers, Flow Cytometers, Consumables, Reagents, Stains, ControlsCalibrators, Others), By Tests (Anemia, Hemoglobinopathy, Leukemia/Lymphoma Phenotyping, Hematology pathophysiology, Complete blood count (CBC), Others) andBy End User (HospitalsClinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Academic Institutes, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Hematology Diagnostics Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Product Type (USD Million)
  49.     4.1.1 Hematology Analyzer
  50.     4.1.2 Flow Cytometer
  51.     4.1.3 Consumable
  52.   4.2 Chemicals and Materials, BY Test Type (USD Million)
  53.     4.2.1 Hemoglobinopathy
  54.     4.2.2 Leukemia Phenotyping
  55.   4.3 Chemicals and Materials, BY End User (USD Million)
  56.     4.3.1 Hospitals & Clinics
  57.     4.3.2 Diagnostic Laboratories
  58. 5 SECTION V: COMPETITIVE ANALYSIS
  59.   5.1 Competitive Landscape
  60.     5.1.1 Overview
  61.     5.1.2 Competitive Analysis
  62.     5.1.3 Market share Analysis
  63.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  64.     5.1.5 Competitive Benchmarking
  65.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  66.     5.1.7 Key developments and growth strategies
  67.       5.1.7.1 New Product Launch/Service Deployment
  68.       5.1.7.2 Merger & Acquisitions
  69.       5.1.7.3 Joint Ventures
  70.     5.1.8 Major Players Financial Matrix
  71.       5.1.8.1 Sales and Operating Income
  72.       5.1.8.2 Major Players R&D Expenditure. 2023
  73.   5.2 Company Profiles
  74.     5.2.1 Abbott Laboratories (US)
  75.       5.2.1.1 Financial Overview
  76.       5.2.1.2 Products Offered
  77.       5.2.1.3 Key Developments
  78.       5.2.1.4 SWOT Analysis
  79.       5.2.1.5 Key Strategies
  80.     5.2.2 Roche Diagnostics (CH)
  81.       5.2.2.1 Financial Overview
  82.       5.2.2.2 Products Offered
  83.       5.2.2.3 Key Developments
  84.       5.2.2.4 SWOT Analysis
  85.       5.2.2.5 Key Strategies
  86.     5.2.3 Siemens Healthineers (DE)
  87.       5.2.3.1 Financial Overview
  88.       5.2.3.2 Products Offered
  89.       5.2.3.3 Key Developments
  90.       5.2.3.4 SWOT Analysis
  91.       5.2.3.5 Key Strategies
  92.     5.2.4 Beckman Coulter (US)
  93.       5.2.4.1 Financial Overview
  94.       5.2.4.2 Products Offered
  95.       5.2.4.3 Key Developments
  96.       5.2.4.4 SWOT Analysis
  97.       5.2.4.5 Key Strategies
  98.     5.2.5 Sysmex Corporation (JP)
  99.       5.2.5.1 Financial Overview
  100.       5.2.5.2 Products Offered
  101.       5.2.5.3 Key Developments
  102.       5.2.5.4 SWOT Analysis
  103.       5.2.5.5 Key Strategies
  104.     5.2.6 Ortho Clinical Diagnostics (US)
  105.       5.2.6.1 Financial Overview
  106.       5.2.6.2 Products Offered
  107.       5.2.6.3 Key Developments
  108.       5.2.6.4 SWOT Analysis
  109.       5.2.6.5 Key Strategies
  110.     5.2.7 HemoCue (SE)
  111.       5.2.7.1 Financial Overview
  112.       5.2.7.2 Products Offered
  113.       5.2.7.3 Key Developments
  114.       5.2.7.4 SWOT Analysis
  115.       5.2.7.5 Key Strategies
  116.     5.2.8 Grifols (ES)
  117.       5.2.8.1 Financial Overview
  118.       5.2.8.2 Products Offered
  119.       5.2.8.3 Key Developments
  120.       5.2.8.4 SWOT Analysis
  121.       5.2.8.5 Key Strategies
  122.     5.2.9 Bio-Rad Laboratories (US)
  123.       5.2.9.1 Financial Overview
  124.       5.2.9.2 Products Offered
  125.       5.2.9.3 Key Developments
  126.       5.2.9.4 SWOT Analysis
  127.       5.2.9.5 Key Strategies
  128.   5.3 Appendix
  129.     5.3.1 References
  130.     5.3.2 Related Reports
  131. 6 LIST OF FIGURES
  132.   6.1 MARKET SYNOPSIS
  133.   6.2 UK MARKET ANALYSIS BY PRODUCT TYPE
  134.   6.3 UK MARKET ANALYSIS BY TEST TYPE
  135.   6.4 UK MARKET ANALYSIS BY END USER
  136.   6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  137.   6.6 RESEARCH PROCESS OF MRFR
  138.   6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  139.   6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  140.   6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  141.   6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  142.   6.11 CHEMICALS AND MATERIALS, BY PRODUCT TYPE, 2024 (% SHARE)
  143.   6.12 CHEMICALS AND MATERIALS, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
  144.   6.13 CHEMICALS AND MATERIALS, BY TEST TYPE, 2024 (% SHARE)
  145.   6.14 CHEMICALS AND MATERIALS, BY TEST TYPE, 2024 TO 2035 (USD Million)
  146.   6.15 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
  147.   6.16 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
  148.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  149. 7 LIST OF TABLES
  150.   7.1 LIST OF ASSUMPTIONS
  151.     7.1.1
  152.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  153.     7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Million)
  154.     7.2.2 BY TEST TYPE, 2025-2035 (USD Million)
  155.     7.2.3 BY END USER, 2025-2035 (USD Million)
  156.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  157.     7.3.1
  158.   7.4 ACQUISITION/PARTNERSHIP
  159.     7.4.1

UK Chemicals and Materials Market Segmentation

Chemicals and Materials By Product Type (USD Million, 2025-2035)

  • Hematology Analyzer
  • Flow Cytometer
  • Consumable

Chemicals and Materials By Test Type (USD Million, 2025-2035)

  • Hemoglobinopathy
  • Leukemia Phenotyping

Chemicals and Materials By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Laboratories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions